Sound wave device clears toxic brain plaques without surgery

Scientists have found a way to clean the brain of Alzheimer’s toxic plaques using nothing but sound waves, and no scalpel is required.

A landmark clinical trial published in the Journal of Neurosurgery confirmed that focused ultrasound technology can reduce amyloid plaques in the brains of Alzheimer’s patients without a single surgical incision.

The study was led by neurosurgeon Dr. Jin Woo Chang at Korea University Anam Hospital in Seoul, and its results, announced in January 2025, are being called a critically important new direction in Alzheimer’s treatment.

The main finding is striking in its simplicity: sound waves, aimed precisely at the brain, can help the body flush out the toxic protein clumps that are a defining feature of Alzheimer’s disease.

No surgery. No implants. No drugs required.

That is the headline. And it is already changing how researchers think about the future of dementia care.

What Are Amyloid Plaques, and Why Do They Matter?

To understand why this discovery matters, it helps to know what these plaques actually are.

Amyloid-beta is a protein fragment that the brain produces naturally and normally clears away during sleep.

In people with Alzheimer’s disease, this clearance system breaks down.

The protein builds up, clumps together, and forms sticky deposits between neurons called amyloid plaques.

These plaques are believed to interfere with communication between brain cells, eventually contributing to the memory loss, confusion, and cognitive decline that define Alzheimer’s disease.

For decades, drug developers have tried to target these plaques with mixed results.

The newer anti-amyloid antibody drugs, such as lecanemab and donanemab, can slow the progression of the disease somewhat, but they cannot reverse it, and they carry significant risks including brain swelling and bleeding.

The search for a safer, more effective approach has been relentless.

Focused ultrasound may be the breakthrough that changes the game.

How the Study Was Conducted

The trial, funded by the Focused Ultrasound Foundation, enrolled six participants with Alzheimer’s disease.

Each participant underwent blood-brain barrier (BBB) opening in both frontal lobes, three times, at two-month intervals.

The BBB is a tightly protective layer of cells lining the brain’s blood vessels.

Its job is to keep harmful substances out of the brain, but it also, unfortunately, keeps most drugs out too.

Focused ultrasound was used to temporarily and safely open this barrier in precisely targeted regions of the brain.

Here is the key detail: no Alzheimer’s drugs were administered alongside the procedure.

The ultrasound alone was being tested for its effect.

The team used positron emission tomography (PET) scans to measure amyloid plaque levels before and after treatment.

They also administered several cognitive and neuropsychiatric tests to track any behavioral changes.

The average volume of brain tissue treated in each session was 43.1 cubic centimeters, which is twice as large as the same researcher’s previous trials and larger than any other prior clinical trial of this kind.

That scale matters, because it meant more amyloid-laden tissue was exposed to the ultrasound’s effects than ever before.

Findings From the Study

The results were quietly remarkable.

Amyloid levels decreased in four of the six participants.

Not just in the regions directly treated, but across the brain more broadly, suggesting a kind of cascading clearance effect that went beyond the targeted area.

Neuropsychiatric symptoms improved in five of the six participants, or 83%, as measured by a standardized caregiver assessment tool.

The two participants whose amyloid levels increased were in the “amyloid-increase group,” and researchers noted this variation as an area requiring further investigation.

Crucially, no serious safety concerns were identified throughout the trial.

The procedure was well tolerated, performed on an outpatient basis, and left participants without the side effects commonly associated with drug-based amyloid treatments.

Separately, researchers at West Virginia University published data in the New England Journal of Medicine showing that focused ultrasound in combination with an anti-amyloid antibody produced an average of 32% more reduction in amyloid-beta plaques in treated brain areas compared to areas that received the antibody alone.

That combination approach opens another door entirely.

The Part Most People Get Wrong About Treating Alzheimer’s

Here is where the thinking around this research gets interesting, and where the conventional wisdom starts to crack.

Most people assume that fighting Alzheimer’s means getting drugs into the brain.

The entire field, for years, has been oriented around finding molecules small enough or clever enough to cross the blood-brain barrier and do their work inside.

Billions of dollars and decades of effort have gone into that approach.

What this new research suggests is something almost the opposite: the real problem may not be getting things into the brain but helping the brain get things out.

Scientists are increasingly focusing on an emerging hypothesis: that in Alzheimer’s patients, the blood-brain barrier itself is impaired.

Not just selective, but actively dysfunctional.

When the barrier is not working properly, the brain’s natural waste-clearing systems, including the glymphatic system that flushes toxins during deep sleep, cannot do their job efficiently.

Amyloid builds up not because the brain is producing too much of it, but because the plumbing to remove it is broken.

Focused ultrasound, in this framing, is not just a delivery mechanism for drugs.

It may be a way of repairing the infrastructure of the brain’s own cleaning system, allowing the body to do what it is already designed to do, but has lost the ability to perform.

That is a fundamentally different model of treatment, and it has profound implications.

How the Science Works: Sound Waves and the Brain

You might be wondering how a sound wave can do something as precise as opening a protective barrier around the brain without causing damage.

The answer lies in a technique called focused ultrasound, which works a lot like using a magnifying glass to concentrate sunlight on a single point.

Multiple beams of ultrasound energy are directed at the brain from outside the skull.

Each individual beam is too weak to cause any effect on its own.

But where they converge, at a pinpoint target deep in the brain tissue, the concentrated energy becomes powerful enough to produce specific, controlled effects.

In this application, tiny microbubbles that circulate in the brain’s capillaries are caused to oscillate by the ultrasound waves.

Their vibrations create temporary, reversible openings in the walls of the blood vessels in the targeted area.

This allows the brain’s natural clearance mechanisms to kick in, and amyloid proteins that have built up in the tissue can move more freely into the bloodstream to be carried away.

The opening lasts only a few hours before the barrier reseals itself naturally.

No permanent structural changes. No damage to surrounding neurons.

As IEEE Pulse reported, this BBB opening has now been demonstrated as safe in multiple clinical trials for conditions including Alzheimer’s disease and brain tumors.

How the Study Applies to Real Life

For the approximately 55 million people worldwide living with dementia, most of whom have Alzheimer’s disease, this research carries the kind of hope that does not come along often.

The immediate practical impact is still some years away.

This was a small, early-phase trial with six participants, and much larger, longer studies are needed before focused ultrasound becomes a standard treatment option.

But several things about this approach make it compelling beyond the numbers.

It is non-invasive. Patients sit in a chair or lie down, and the procedure is performed from outside the body entirely.

It is outpatient-friendly. The trial participants were not hospitalized. The procedure fits within the kind of care model that aging patients and their families can actually navigate.

It may work without drugs. For patients who cannot tolerate the side effects of anti-amyloid antibodies, or for whom those drugs are contraindicated, a drug-free approach to plaque reduction would be transformative.

It could be combined with existing therapies. The West Virginia University data suggests that pairing focused ultrasound with current drug treatments significantly boosts their effectiveness, potentially reducing the doses needed and therefore the associated risks.

What Comes Next for Focused Ultrasound

Dr. Chang has described this trial as the foundation for future studies that will combine BBB opening with drug delivery, testing whether the pairing accelerates results even further.

Larger multicenter trials are being planned.

Researchers are also exploring whether focused ultrasound can be used earlier in the disease process, before symptoms become severe, as a preventive or early-intervention tool.

Separately, MIT researchers have been investigating a related but distinct approach: using 40 Hz sound waves to stimulate gamma brain rhythms and activate the brain’s immune cells, called microglia, to clear plaques.

In animal models, this method reduced plaques by up to 50%, and early human trials have shown promising cognitive results.

These are different mechanisms heading in the same direction, a convergence that suggests the field is genuinely closing in on something.

A Shift in How We Think About the Brain

What makes this moment feel different from previous Alzheimer’s breakthroughs is the shift in underlying logic.

For most of modern medicine, the brain has been treated as a fortress to conquer, a place drugs need to penetrate and enemies need to be destroyed.

This new wave of research treats it more like a system to be maintained, a network with its own cleaning schedules, drainage channels, and self-repair functions that can be supported or restored.

Focused ultrasound is not attacking Alzheimer’s directly. It is restoring the conditions under which the brain can defend itself.

That is a quieter kind of medicine. Less dramatic than a targeted drug or gene therapy. But potentially more durable, more tolerable, and more aligned with how the brain actually works.

For the millions of families watching a loved one move through the stages of this disease, waiting for a treatment that is both effective and livable, that shift in thinking may matter as much as the science itself.

References and Further Reading